Safety and immunogenicity of VPM1002 versus BCG in South African newborn 
babies: a randomised, phase 2 non-inferiority double-blind controlled trial

Cotton, Marc F.; Madhi, Shabir A.; Luabeya , Angelique K.; Tameris , Michele; Hesseling, Anneke C; Shenje, Justin; Schoeman, Elisma; Hatherill , Mark; Desai , Sajjad; Kapse, Dhananjay; Brückner , Sina; Koen , Anthonet; Jose , Lisa; Moultrie , Andrew; Bhikha , Sutika; Walzl , Gerhard; Gutschmidt , Andrea; Kotze , Leigh A.; Allies , Devon L.; Loxton , Andre G; Shaligram , Umesh; Abraham , Maria; Johnstone , Hilary; Grode , Leander; Kaufmann, Stefan H. E.; Kulkarni , Prasad S

doi:10.1016/S1473-3099(22)00222-5

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial

MPS-Authors

/persons/resource/persons248446

Kaufmann, Stefan H. E.
Emeritus Group Systems Immunology, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Cotton, M. F., Madhi, S. A., Luabeya, A. K., Tameris, M., Hesseling, A. C., Shenje, J., et al. (2022). Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. The Lancet Infectious Diseases, 22(10), 1472-1483. doi:10.1016/S1473-3099(22)00222-5.

Cite as: https://hdl.handle.net/21.11116/0000-000B-C9C8-1

Abstract

There is no abstract available